Key result
Trimetazidine added to standard therapy cuts weekly angina attacks ~70% in stable angina with HF.
Why the study?
To evaluate the efficacy of modified-release trimetazidine added to standard therapy in patients with stable angina and chronic heart failure as part of the PERSPECTIVE study.
Does modified-release trimetazidine reduce angina attacks and improve clinical outcomes in patients with stable angina and chronic heart failure?
RCT (n=806)
Open-label
Randomized
Yes
Does modified-release trimetazidine reduce angina attacks and improve clinical outcomes in patients with stable angina and chronic heart failure?
The addition of modified-release trimetazidine to standard therapy significantly reduces angina frequency, improves echocardiographic parameters, and lowers hospitalization rates in patients with stable angina and chronic heart failure.
Answers are grounded in this paper and cite their sources.
Trimetazidine addition was associated with fewer angina attacks and hospitalizations; leaves open need for randomized confirmation in stable angina with heart failure.
Aim To evaluate efficacy of modified-release trimetazidine (TMZ) included into the standard therapy for patients with stable angina and chronic heart failure (CHF) as a part of a subgroup analysis in the PERSPECTIVE study.Material and methods The study included 806 patients: group 1 (n=691), patients receiving a standard therapy and modified-release TMZ (TMZ group); and group 2 (n=115), patients receiving a standard therapy (control group). Total duration of the study was 12 months.Results In the TMZ group, the weekly number of angina attacks decreased by 41.9% (p<0.0001) in 2 months and by 69.6 % (from baseline, р<0.0001) in 12 months, and the frequency of nitroglycerine dosing decreased by 40.8 % (р<0.0001) and 67.7 % (р<0.0001), respectively. In the control group, the respective values did not change. In the TMZ group compared to the control group, the QT interval was shorter (7.9 %; р<0.05), the left ventricular (LV) end-systolic dimension was reduced (13.4 %; р<0.01), interventricular septal thickness and LV posterior wall thickness were decreased (9.5 %; р<0.01 and 12.2 %; р<0.01, respectively), and the ejection fraction was increased (11.4; р<0.05). Following the TMZ treatment, the leukocyte count in peripheral blood was decreased (5.3 %; р<0.01) and the serum concentration of high-sensitivity C-reactive protein was decreased (30.7 %; р<0.01) vs. increases of these indexes in the control group (17.9 %; р<0.05 and 17.8 %; р<0.05, respectively). The proportion of patients hospitalized for exacerbation of CHF or angina for 12 months was 8.6 % in the TMZ group and 15.7 % in the control group (p=0,001).Conclusion In patients with stable angina and CHF, inclusion of modified-release TMZ into the standard therapy decreases the number of angina attacks, reduces the activity of inflammatory factors, and improves the course of disease.
No takes yet. Share an insight, caveat, or question.
Бубнова et al. (2021) conducted an RCT in Stable angina and chronic heart failure (n=806). Modified-release trimetazidine vs. Standard therapy alone was evaluated on Weekly number of angina attacks at 12 months (p=<0.0001). Modified-release trimetazidine added to standard therapy significantly reduced the weekly number of angina attacks by 69.6% at 12 months compared to standard therapy alone in patients with stable angina and chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: